User profiles for MICHAEL KREUTER

Michael Kreuter

Mainz Center for pulmonary diseases, University of Mainz and Marienhaus Klinikum Mainz …
Verified email at marienhaus.de
Cited by 16068

SARS‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells

…, C Veith, AW Boots, BP Hennig, M Kreuter… - The EMBO …, 2020 - embopress.org
The SARS ‐CoV‐2 pandemic affecting the human respiratory system severely challenges
public health and urgently demands for increasing our understanding of COVID ‐19 …

Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline

…, Y Inoue, T Johkoh, M Kreuter… - American Journal of …, 2022 - atsjournals.org
Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …

Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline

…, CJ Ryerson, JL Myers, M Kreuter… - American journal of …, 2020 - atsjournals.org
Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It
represents a collaborative effort among the American Thoracic Society, Japanese …

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo …

J Behr, A Prasse, M Kreuter, J Johow… - The Lancet …, 2021 - thelancet.com
Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …

[HTML][HTML] Global incidence and prevalence of idiopathic pulmonary fibrosis

…, J Langley, G Smith, JM Khalid, H Patel, M Kreuter - Respiratory …, 2021 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease
with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of …

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

TM Maher, TJ Corte, A Fischer, M Kreuter… - The lancet Respiratory …, 2020 - thelancet.com
Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …

Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study

…, M Jones, S Jones, M Kokosi, M Kreuter… - American journal of …, 2020 - atsjournals.org
Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …

[HTML][HTML] Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype

…, A Shimizu, A Kaipainen, M Kreuter… - The Journal of …, 2004 - Am Soc Clin Investig
Melanoma is the most lethal skin cancer. Most deaths from melanoma result from metastases.
Semaphorins have been shown to inhibit neuronal and endothelial cell migration, but the …

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

PM George, P Spagnolo, M Kreuter… - The lancet Respiratory …, 2020 - thelancet.com
Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

[HTML][HTML] Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical …

…, S Schmiedel, MM Addo, F Herth, M Kreuter… - Nature Cancer, 2023 - nature.com
Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …